Healthcare Services

Low-Grade Glioma Market to Reach $1.94 Billion by 2030 at 5.6% CAGR

April 23, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Low-Grade Glioma Market During The Forecast Period?

The low-grade glioma market size has experienced strong growth in recent years. It is forecast to grow from $1.47 billion in 2025 to $1.56 billion in 2026, at a compound annual growth rate (CAGR) of 5.9%. The market’s expansion in the past can be linked to advancements in neuroimaging technologies, improved survival rates in low-grade glioma patients, increased neurosurgical intervention rates, growing awareness of brain tumor symptoms, and the expansion of oncology treatment centers.

The low-grade glioma market size is projected to experience substantial growth in the upcoming years, with an expectation to reach $1.94 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.6%. This expansion during the forecast period is attributable to an increasing emphasis on molecular tumor profiling, a rise in investment in targeted oncology drugs, a growing demand for less aggressive treatment options, broadening access to specialized neuro-oncology care, and ongoing clinical trials for novel therapies. Major trends identified for the forecast period include a heightened focus on early diagnosis and monitoring, the increasing adoption of targeted drug therapies, a growing preference for multimodal treatment approaches, an expansion of personalized treatment planning, and developing long-term disease management strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Which Strong Drivers Are Impacting The Low-Grade Glioma Market Growth?

An anticipated increase in brain tumor occurrences is projected to stimulate the expansion of the low-grade glioma market in the future. A brain tumor refers to an anomalous cellular proliferation within or near the brain, potentially being either non-cancerous or cancerous. This escalating frequency of brain tumors is attributed to elements such as heightened radiation exposure, environmental contaminants, inherited susceptibility, and advancing age. Low-grade glioma plays a beneficial role in addressing brain tumors through the deployment of sophisticated diagnostic methods and specific treatments like surgery, radiation, and chemotherapy. These interventions are instrumental in delaying tumor advancement, maintaining brain function, and enhancing patient results, underscoring the vital importance of prompt diagnosis and tailored interventions for similar brain tumor types. For example, in October 2025, data from the Australia-based government agency Cancer Australia indicated that in 2023, Australia documented 1,597 deaths from brain cancer (956 men and 641 women). This figure is anticipated to increase marginally to 1,639 deaths (979 men and 660 women) by 2025. The projected likelihood of succumbing to brain cancer by age 85 in 2025 stands at 1 in 195 (0.51%), with males facing a greater risk at 1 in 165 (0.61%) and females a lesser risk at 1 in 240 (0.42%). Consequently, the escalating occurrence of brain tumors is fueling the expansion of the low-grade glioma market.

What Segment Categories Shape The Low-Grade Glioma Market Segment Landscape?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

Which Trends Are Contributing To Changes In The Low-Grade Glioma Market?

Companies prominently involved in the low-grade glioma market are increasingly focusing on incorporating combination therapies and targeted treatment approaches, such as genetic alteration drugs. This strategy aims to secure a competitive edge and enhance the management of low-grade glioma in children. Genetic alteration drugs are targeted therapies crafted to modify or inhibit specific genetic mutations or cellular abnormalities, thereby aiding in the treatment of diseases like cancer by blocking the pathways that drive uncontrolled cell growth. For example, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, introduced Tovorafenib (Ojemda) after it received accelerated FDA approval. This targeted therapy is specifically developed for children aged six months and older who have unresectable or recurrent low-grade glioma (LGG) with BRAF gene alterations. Delivering a convenient once-weekly oral treatment, it addresses a critical unmet need for pediatric LGG patients who have had restricted prior treatment options.

Who Are The Companies Operating Across The Low-Grade Glioma Market Value Chain?

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

Get The Full Low-Grade Glioma Market Report:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Where Is The Low-Grade Glioma Market Most Concentrated Geographically?

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Low-Grade Glioma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2026, By The Business Research Company

Respiratory Devices And Equipment Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disease Drugs Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Respiratory Devices And Equipment Therapeutic And Diagnostic Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795